Clinical trial
A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.
NCT00191906 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2005
- Completion date
- December 31, 2007
- Enrollment
- 121 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
attention deficit hyperactivity disorder, reading disorder